Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

der a federal contract worth up to $44.4 million. This contract, which is funding work at Peregrine and at several collaborating institutions, was awarded based on positive data from earlier studies in animals infected with VHF that was funded by a previous grant from NIAID.

Bavituximab, which is Peregrine's most advanced PS-targeting antibody, is currently being studied in a clinical trial for the treatment of patients co-infected with HCV and HIV. Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity. Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's collaborators at UT Southwestern Medical Center, the University of Utah at Logan and the University of Texas Medical Branch at Galveston also contributed to this research. The poster, "Phosphatidylserine-Targeting Antibodies as Therapeutic Agents for Viral Hemorrhagic Fever Infections," A. Brideau-Andersen, M. Soares, P. Thorpe, B. Gowen, J. Julander, A. Grant, C.J. Peters, W. Chu, S. Hirst, M. Wakabayashi, K. Schlunegger, B. Freimark, was presented on November 17, 2009 at the 2009 Chemical and Biological Defense Science and Technology Conference.

About Phosphatidylserine (PS)-Targeting Antiviral Agents

PS, a lipid molecule normally found only on the inside of cell membranes, becomes exposed on the outside of the membranes of viruses and virally infected cells. A rapidly growing body of published scientific research confirms that exposed PS is directly involved in the pathogenesis of many serious infectious diseases. Exposed PS enables viruses to evade immune recognition and dampens the body's normal responses to infection. By masking the exposed PS, PS-targeting antibodies are believed to block these effects, allowing the body to develop a robust immune response to the pathogen. P
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (August 22nd), in the scientific journal PLoS ... establish the effect of serotonin on sensitivity to ... optical techniques., "Serotonin is a small molecule known ... brain functions, from the control of sleep and ... This neurotransmitter is also popularly thought to contribute ...
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and China Gel Permeation Chromatography (GPC) Industry Report ... The Global and China Gel Permeation Chromatography (GPC) Industry ... current state of the global gel permeation chromatography industry ... report provides a basic overview of the industry including ...
(Date:8/22/2014)... “Our nation's healthcare system is ... disgrace. Furthermore, every governmental and professional entity that ... state of unorganized dysfunction shares in that enormous ... serve as a device to use in an ... that have accumulated through the years leading to ...
(Date:8/21/2014)... Dallas, Texas (PRWEB) August 21, 2014 ... Global Seaweed Fertilizer Industry” is a professional ... Fertilizer market. The report provides basic Seaweed ... application, and industry chain structure as well ... international market analysis, including domestic market as ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... the graduate education division of the National Science ... to a multidisciplinary research team at Stevens Institute ... Chassapis, Director of the Mechanical Engineering Department. In ... Investigator, the team includes Associate Professor Sven Esche ...
... GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today ... quarter and year ended,December 31, 2007., ... because of the,advancements made for the laboratory-developed ...
... a.m. EDT, NEW YORK and HAIKOU CITY, ... ("China Pharma") (OTC Bulletin Board: CPHI),which develops, manufactures, ... today announced it will release its,Fourth Quarter and ... In,conjunction, the Company will host an earnings conference ...
Cached Biology Technology:Chassapis and team awarded $3 million GK-12 grant from NSF for multiscale research 2Chassapis and team awarded $3 million GK-12 grant from NSF for multiscale research 3GeneNews announces 2007 year end results 2GeneNews announces 2007 year end results 3GeneNews announces 2007 year end results 4GeneNews announces 2007 year end results 5GeneNews announces 2007 year end results 6GeneNews announces 2007 year end results 7GeneNews announces 2007 year end results 8GeneNews announces 2007 year end results 9GeneNews announces 2007 year end results 10China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results 2
(Date:8/22/2014)... Thanks to important discoveries in basic and clinical ... has mobilized into a complex offensive spanning multiple ... Alberta chemistry lab could help find new and ... a compound that targets a specific enzyme overexpressed ... in cells from brain tumours. , Chemistry professor ...
(Date:8/22/2014)... 3β-Hydroxysteroid-Δ24 reductase (DHCR24) is a multifunctional ... reticulum and has neuroprotective and cholesterol-synthesizing ... apoptosis caused by amyloid β deposition. ... Liaoning University in China constructed two ... drive DHCR24 expression specifically in neuronal ...
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... with theatre, much less mate with artistic vigor, but ... recent production Heuschrecken [The Locusts] developed by Stefan Kaegi ... University,s Manfred Laubichler and Gitta Honegger who review the ... Science . "Scientists have no trouble seeing ...
... the Association for Molecular Pathology (AMP) released its ... developed tests (LDTs), a recent focus of debate among ... AMP,s statement outlines the organization,s commitment to providing high ... implementation of appropriate oversight mechanisms. The association also ...
... January 27, 2010 -- Investigators at Sanford-Burnham Medical Research ... surface protein, CD44, helps specific T helper (Th1) cells ... and colleagues determined that without CD44, Th1 cells died ... to generate immunologic memory. This is the first time ...
Cached Biology News:Scientists and cast of thousands swarm stage in Europe 2Scientists and cast of thousands swarm stage in Europe 3AMP releases statement on oversight of laboratory tests 2Secrets of immunologic memory 2
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... x 3 nmol (individual) with sequence ... specifically targeted to your target gene of interestis ... you get more than 75% knockdown of your ... nM siRNA for transfection and confirmation of optimal ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... The IDS 25-Hydroxy Vitamin D ... the quantitative determination of 25-hydroxyvitamin D ... in human serum or plasma. Our ... inconvenience of solvent precipitation and centrifugation ...
Biology Products: